Podcast: This Week in Managed Care&amp;mdash;CAR T Therapy Coverage and Other Health News

Mustang Bio Seeks to Bring CD20-Targeted CAR-T MB-106 From Cancer to Autoimmune Disease

An interim analysis of a phase 1/2 study suggest the REGENXBIO therapy also showed efficacy signals.

Manuel Litchman, MD, the president and chief executive officer of Mustang

Tr1X’s Allogeneic Treg Therapy TRX103 Cleared for US Trial for Preventing GvHD

The specific autoimmune disease(s) that will be evaluated in the trial is as of yet undetermined, but the company hopes to initiate the trial in Q4 of 2024.

Monzr M. Al Malki, MD, the lead investigator of the phase 1 study, an associate professor in the Department of Hematology & Hematopoietic Cell Transplantation, and the director of the Unrelated Donor, Haploidentical, and Cord Blood Transplant Programs at City of Hope National Medical Center

AskBio Evaluates ACTUS-101 Gene Therapy for Late-Onset Pompe Disease

In light of the IND clearance, Tr1X anticipates initiating a phase 1 clinical trial within the second quarter of this year.

Overcoming Challenges With Preclinical Modeling for Cell Therapy in Autoimmune Disease

The more recent data were presented at the 2022 ASGCT Meeting.

Tiffany Chen, PhD, the vice president of discovery at GentiBio

A Closer Look at Pricing for Cell and Gene Therapy

Tiffany Chen, PhD, the vice president of discovery at GentiBio, discussed the general and unique challenges of transitioning cell therapies to clinical trials in autoimmune disease.

Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute

April 14th 2024

RGX-202 Is Well-Tolerated At Multiple Doses Among Patients With DMD

Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute, discussed his research on the value of advanced therapeutics.

Related Content

Mustang Bio Seeks to Bring CD20-Targeted CAR-T MB-106 From Cancer to Autoimmune Disease

An interim analysis of a phase 1/2 study suggest the REGENXBIO therapy also showed efficacy signals.

Tr1X’s Allogeneic Treg Therapy TRX103 Cleared for US Trial for Preventing GvHD

The specific autoimmune disease(s) that will be evaluated in the trial is as of yet undetermined, but the company hopes to initiate the trial in Q4 of 2024.

AskBio Evaluates ACTUS-101 Gene Therapy for Late-Onset Pompe Disease

In light of the IND clearance, Tr1X anticipates initiating a phase 1 clinical trial within the second quarter of this year.

Overcoming Challenges With Preclinical Modeling for Cell Therapy in Autoimmune Disease

The more recent data were presented at the 2022 ASGCT Meeting.

A Closer Look at Pricing for Cell and Gene Therapy

Tiffany Chen, PhD, the vice president of discovery at GentiBio, discussed the general and unique challenges of transitioning cell therapies to clinical trials in autoimmune disease.

April 14th 2024